(Q34975404)

5 August 2017

0 references

Low- versus high-dose rituximab for rheumatoid arthritis: a systematic review and meta-analysis (English)

1 reference

5 August 2017

0 references

1 reference

1 reference

1 reference

Markus Bredemeier

1

0 references

author name string

Fernando K de Oliveira

series ordinal

2

1 reference

5 August 2017

Cláudia M Rocha

series ordinal

3

1 reference

5 August 2017

publication date

1 February 2014

1 reference

Arthritis Care and Research

5 August 2017

published in

1 reference

5 August 2017

volume

66

1 reference

5 August 2017

issue

2

1 reference

5 August 2017

page(s)

228-235

1 reference

2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

5 August 2017

cites work

1 reference

Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis

21 January 2018

1 reference

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

21 January 2018

1 reference

Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial

21 January 2018

1 reference

Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab'

21 January 2018

1 reference

Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR)

21 January 2018

1 reference

Reduced-dose rituximab in rheumatoid arthritis: efficacy depends on degree of B cell depletion.

21 January 2018

1 reference

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

21 January 2018

1 reference

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

21 January 2018

1 reference

The efficacy and safety of rituximab for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials

21 January 2018

1 reference

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

21 January 2018

1 reference

A systematic review identifies a lack of standardization in methods for handling missing variance data

21 January 2018

1 reference

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

21 January 2018

1 reference

Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis

21 January 2018

1 reference

Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II.

21 January 2018

1 reference

Choice of delta: requirements and reality--results of a systematic review

21 January 2018

1 reference

Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis previously untreated with methotrexate.

21 January 2018

1 reference

Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE.

21 January 2018

1 reference

Rituximab use in everyday clinical practice as a first-line biologic therapy for the treatment of DMARD-resistant rheumatoid arthritis.

21 January 2018

1 reference

A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis

21 January 2018

1 reference

21 January 2018

1 reference

New antirheumatic drugs: any real added value? A critical overview of regulatory criteria for their marketing approval

21 January 2018

1 reference

Intention-to-treat concept: A review

21 January 2018

1 reference

Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections

21 January 2018

1 reference

Safety of rituximab in rheumatoid arthritis: a long-term prospective single-center study of gammaglobulin concentrations and infections

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/ACR.22116

1 reference

5 August 2017

1 reference